Document:

Convertible Note Purchase Agreement

 Exhibit 10.35 
  
 $50,000,000 
  
 DURECT CORPORATION 
  
 6.25% CONVERTIBLE NOTES DUE 2008 
  
 PURCHASE AGREEMENT 
  
 June 12, 2003 

 June 12, 2003 
  
 Morgan Stanley & Co. Incorporated 
 1585 Broadway 
 New York, New York 10036 
  
 Dear Sirs and Mesdames: 
  
 DURECT Corporation, a Delaware corporation (the “Company”),
proposes to issue and sell to Morgan Stanley & Co. Incorporated (the “Initial Purchaser”) $50,000,000 principal amount of its 6.25% Convertible Notes due 2008 (the “Firm Securities”) to be issued pursuant to the
provisions of an Indenture dated as of June 18, 2003 (the “Indenture”) between the Company and The Bank of New York, as Trustee (the “Trustee”). The Company also proposes to issue and sell to the Initial Purchaser
not more than an additional $10,000,000 principal amount of its 6.25% Convertible Notes due 2008 (the “Additional Securities”) if and to the extent that the Initial Purchaser shall have determined to exercise the right to purchase
such 6.25% Convertible Notes due 2008 granted to the Initial Purchaser in Section 2 hereof. The Firm Securities and the Additional Securities are hereinafter collectively referred to as the “Securities”. The Securities will be
convertible into shares of common stock, par value $0.0001 per share, of the Company together with the rights evidenced by such common stock to the extent provided in the Preferred Shares Rights Agreement dated as of July 6, 2001 between the Company
and EquiServe Trust Company, N.A. (unless such rights shall have been redeemed or terminated previously) (the “Underlying Securities”). 
  
 The Securities and the Underlying Securities will be offered without being registered under the Securities Act of 1933, as amended (the
“Securities Act”), to qualified institutional buyers in compliance with the exemption from registration provided by Rule 144A under the Securities Act. 
  
 The Initial Purchaser and its direct and indirect transferees will be entitled to the benefits of a Registration Rights
Agreement dated the Closing Date (as defined herein) between the Company and the Initial Purchaser (the “Registration Rights Agreement”). 
  
 In connection with the sale of the Securities, the Company has prepared an offering memorandum (the “Memorandum”) including or
incorporating by reference a description of the terms of the Securities and the Underlying Securities, the terms of the offering and a description of the Company. As used herein, the term “Memorandum” shall include the documents
incorporated by reference therein. The terms “supplement”, “amendment” and “amend” as used herein with respect to the Memorandum shall include all documents deemed to be incorporated by reference in
the Memorandum that are filed subsequent to the date of the Memorandum with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 1. Representations and Warranties. The Company represents and warrants to, and agrees with, you
that: 
  
 (a) (i) The Memorandum does not contain
and, as amended or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading and (ii) the
Memorandum does not contain and, as amended or supplemented, if applicable, will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading, except that the representations and warranties set forth in this paragraph do not apply to statements or omissions in the Memorandum based upon information relating to the Initial Purchaser furnished to the
Company in writing by the Initial Purchaser expressly for use therein. 
  
 (b) (i) Each document, if any, filed or to be filed pursuant to the Exchange Act and incorporated by reference in the Memorandum complied or will comply when so filed in all material respects with the Exchange Act and
the applicable rules and regulations of the Commission thereunder and (ii) the Memorandum, in the form used by the Initial Purchaser to confirm sales and on the Closing Date (as defined in Section 4), will not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this paragraph do not
apply to statements or omissions in the Memorandum based upon information relating to the Initial Purchaser furnished to the Company in writing by the Initial Purchaser expressly for use therein. 
  
 (c) The Company has been duly incorporated, is validly
existing as a corporation in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Memorandum and is duly qualified to
transact business and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing
would not have a material adverse effect on the Company and its subsidiaries, taken as a whole. 
  
 (d) Each subsidiary of the Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the
jurisdiction of its incorporation, has the corporate power and authority to own its property and to conduct its business as described in the Memorandum and is duly qualified to transact business and is in good standing in each jurisdiction in which
the conduct of its business or its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the Company and its
subsidiaries, taken as a whole; all of the issued shares of capital stock of each subsidiary of the Company have been duly and validly authorized and 
  

 2 

 
issued, are fully paid and non-assessable and are owned directly by the Company, free and clear of all liens, encumbrances, equities or claims. 

 
 (e) This Agreement has been duly authorized, executed and
delivered by the Company. 
  
 (f) The authorized
capital stock of the Company conforms as to legal matters to the description thereof contained in the Memorandum. 
  
 (g) The shares of common stock of the Company outstanding prior to the issuance of the Securities have been duly authorized and are
validly issued, fully paid and non-assessable. 
  
 (h) The Securities have been duly authorized and, when executed and authenticated in accordance with the provisions of the Indenture and delivered to and paid for by the Initial Purchaser in accordance with the terms of this Agreement, will
be valid and binding obligations of the Company, enforceable in accordance with their terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and equitable principles of general applicability,
and will be entitled to the benefits of the Indenture and the Registration Rights Agreement pursuant to which such Securities are to be issued. 
  
 (i) The Underlying Securities issuable upon conversion of the Securities have been duly authorized and reserved and, when issued upon
conversion of the Securities in accordance with the terms of the Securities, will be validly issued, fully paid and non-assessable, and the issuance of the Underlying Securities will not be subject to any preemptive or similar rights. 
  
 (j) Each of the Indenture and the Registration Rights
Agreement has been duly authorized, executed and delivered by, and (assuming the due authorization, execution and delivery thereof by the other parties thereto) is a valid and binding agreement of, the Company, enforceable in accordance with its
terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and equitable principles of general applicability and except as rights to indemnification and contribution under the Registration Rights
Agreement may be limited under applicable law. 
  
 (k) The execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement, the Indenture, the Registration Rights Agreement and the Securities will not contravene any provision of
applicable law or the certificate of incorporation or by-laws of the Company or any agreement or other instrument binding upon the Company or any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, or any
judgment, order or decree of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, and no consent, approval, authorization or order of, or qualification with, any 
  

 3 

 
governmental body or agency is required for the performance by the Company of its obligations under this Agreement, the Indenture, the Registration Rights
Agreement or the Securities, except such as may be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of the Securities and by Federal and state securities laws with respect to the Company’s
obligations under the Registration Rights Agreement. 
  
 (l) There has not occurred any material adverse change, or any development involving a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its
subsidiaries, taken as a whole, from that set forth in the Memorandum provided to prospective purchasers of the Securities. 
  
 (m) Neither the Company nor any of its subsidiaries is in violation of its respective charter or by-laws or in default in the performance
of any obligation, agreement, covenant or condition contained in any indenture, loan agreement, mortgage, lease or other agreement or instrument that is material to the Company and its subsidiaries, taken as a whole, to which the Company or any of
its subsidiaries is a party or by which the Company or any of its subsidiaries or their respective property is bound, except for such defaults that would not, singly or in the aggregate, have a material adverse effect on the Company and its
subsidiaries, taken as a whole. 
  
 (n) There are
no legal or governmental proceedings pending or, to the knowledge of the Company, threatened to which the Company or any of its subsidiaries is a party or to which any of the properties of the Company or any of its subsidiaries is subject other than
proceedings accurately described in all material respects in the Memorandum and proceedings that would not have a material adverse effect on the Company and its subsidiaries, taken as a whole, or on the power or ability of the Company to perform its
obligations under this Agreement, the Indenture, the Registration Rights Agreement or the Securities or to consummate the transactions contemplated by the Memorandum. 
  
 (o) The Company and its subsidiaries (i) are in compliance with any and all applicable foreign, federal,
state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received all
permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where such
noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate, have a material
adverse effect on the Company and its subsidiaries, taken as a whole. 
  

 4 

 (p) There are no costs or liabilities associated with Environmental Laws (including,
without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential
liabilities to third parties) which would, singly or in the aggregate, have a material adverse effect on the Company and its subsidiaries, taken as a whole. 
  
 (q) The Company is not, and after giving effect to the offering and sale of the Securities and the application of the proceeds thereof as
described in the Memorandum will not be, required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended. 
  
 (r) Since September 28, 2000, neither the Company nor any affiliate (as defined in Rule 501(b) of Regulation
D under the Securities Act, an “Affiliate”) of the Company has directly, or through any agent, (i) sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities
Act) which is or will be integrated with the sale of the Securities in a manner that would require the registration under the Securities Act of the Securities or (ii) offered, solicited offers to buy or sold the Securities by any form of general
solicitation or general advertising (as those terms are used in Regulation D under the Securities Act) or in any manner involving a public offering within the meaning of Section 4(2) of the Securities Act. 
  
 (s) Subject to the accuracy of the Initial Purchaser’s
representations, warranties and covenants contained herein, it is not necessary in connection with the offer, sale and delivery of the Securities to the Initial Purchaser in the manner contemplated by this Agreement to register the Securities under
the Securities Act or to qualify the Indenture under the Trust Indenture Act of 1939, as amended. 
  
 (t) The Securities satisfy the requirements set forth in Rule 144A(d)(3) under the Securities Act. 
  
 (u) The Company has established and maintained disclosure
controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) that are adequate and effective and designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to its
chief executive officer and chief financial officer by others within those entities. 
  
 (v) The Company maintains a system of accounting controls sufficient to provide reasonable assurances that (i) transactions are executed
in accordance with management’s general or specific authorization, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain
accountability for assets, (iii) access to assets is permitted only in accordance with management’s general or specific authorization and (iv) the recorded accountability for assets is compared with existing 
  

 5 

 
assets at reasonable intervals and appropriate action is taken with respect to any differences. 
  
 (w) Except as described in the Memorandum, the Company and
its subsidiaries own, possess or can acquire on reasonable terms all material patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures), trademarks, service marks and trade names currently employed by them in connection with the business now operated by them, and neither the Company nor any of its subsidiaries has received any notice of
infringement or of conflict with asserted rights of others with respect to any of the foregoing which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a material adverse effect on the Company and
its subsidiaries, taken as a whole. 
  
 (x) The
Company and its subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses, and neither the Company nor any of its
subsidiaries has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would
have a material adverse effect on the Company and its subsidiaries, taken as a whole, except as described in the Memorandum. 
  
 (y) The Company and its subsidiaries do not own any real property and have good and marketable title to all personal property owned by
them which is material to the business of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as are described in the Memorandum or such as do not materially affect the value of such
property and do not interfere with the use made and proposed to be made of such property by the Company and its subsidiaries; and any real property and buildings held under lease by the Company and its subsidiaries are held by them under valid,
subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries, in each case except as described in the
Memorandum. 
  
 (z) The Company and its
subsidiaries are insured by the insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which they are engaged; neither the Company nor any of its
subsidiaries has been refused any insurance coverage sought or applied for; and neither the Company nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a material adverse effect on the Company and its subsidiaries, taken as a whole, except as described in the
Memorandum. 
  

 6 

 (aa) No material labor dispute with the employees of the Company or any of its
subsidiaries exists, except as described in the Memorandum, or, to the knowledge of the Company, is imminent; and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers,
manufacturers or contractors that could have a material adverse effect on the Company and its subsidiaries, taken as a whole. 
  
 (bb) The consolidated financial statements included or incorporated by reference in the Memorandum, together with related schedules and
notes, present fairly the consolidated financial position, results of operations and changes in financial position of the Company and its subsidiaries on the basis stated therein at the respective dates or for the respective periods to which they
apply; such statements and related schedules and notes have been prepared in accordance with generally accepted accounting principles consistently applied throughout the periods involved, except as disclosed therein; and the other financial and
statistical information and data set forth in the Memorandum are, in all material respects, accurately presented and prepared on a basis consistent with such financial statements and the books and records of the Company. 
  
 (cc) The descriptions of the results of studies, tests and
preclinical and clinical trials conducted by or on behalf of the Company contained in the Memorandum are accurate and complete in all material respects and, except as described in the Memorandum, the Company has not received any notices or
correspondence from the U.S. Food and Drug Administration or any state, local or foreign governmental body exercising comparable authority requiring the termination, suspension or material modification of any studies, tests or preclinical or
clinical trials conducted by or on behalf of the Company which termination, suspension or material modification would have a material adverse effect on the Company and its subsidiaries, taken as a whole. 
  
 (dd) Subsequent to the date as of which information is given
in the Memorandum (i) the Company has not reached any understanding, whether or not in writing, regarding potential terms with respect to any transaction that would constitute a business combination under Regulation S-X 11-01(a), where the business
to be acquired would constitute a significant subsidiary as defined in Rule 1-02(w) at the 10% level; (ii) the Company has not purchased any of its outstanding capital stock, nor declared, paid or otherwise made any dividend or distribution of any
kind on its capital stock other than ordinary and customary dividends or repurchases of unvested shares of capital stock from directors, employees, consultants or other service providers in connection with the termination of such person’s
relationship with the Company; and (iii) there has not been any material change in the capital stock, short-term debt or long-term debt of the Company and its subsidiaries, except in each case as described in the Memorandum. 
  
 2. Agreements to Sell and Purchase. The Company hereby agrees to sell
to the Initial Purchaser, and the Initial Purchaser, upon the basis of the representations and warranties herein contained, but subject to the conditions hereinafter stated, agrees to purchase from the Company 
  

 7 

 
$50,000,000 principal amount of Firm Securities at a purchase price of 95.00% of the principal amount thereof (the “Purchase Price”) plus
accrued interest, if any, to the Closing Date. 
  
 On the basis of
the representations and warranties contained in this Agreement, and subject to its terms and conditions, the Company agrees to sell to the Initial Purchaser the Additional Securities, and the Initial Purchaser shall have the right to purchase up to
$10,000,000 principal amount of Additional Securities at the Purchase Price plus accrued interest, if any, to the date of payment and delivery. The Initial Purchaser may exercise this right in whole or from time to time in part by giving written
notice not later than 30 days after the date of this Agreement. Any exercise notice shall specify the principal amount of Additional Securities to be purchased by the Initial Purchaser and the date on which such Additional Securities are to be
purchased. Each purchase date must be at least one business day after the written notice is given and may not be earlier than the closing date for the Firm Securities nor later than ten business days after the date of such notice. 
  
 The Company hereby agrees that, without the prior written consent of Morgan
Stanley & Co. Incorporated, it will not, during the period ending 90 days after the date of the Memorandum, (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock of the Company or any securities convertible into or exercisable or exchangeable for common stock of the Company or
(ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock of the Company, whether any such transaction described in clause (i) or (ii) above is to
be settled by delivery of common stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to (A) the sale of the Securities under this Agreement, (B) the issuance by the Company of any shares of common stock upon
the exercise of an option or warrant or the conversion of the Securities or of a security outstanding on the date hereof, (C) the grant by the Company of options to directors, employees, consultants or other service providers of the Company and its
subsidiaries in the ordinary course of business, (D) any shares of Common Stock or other rights to acquire shares of capital stock of the Company issued pursuant to equipment financing, lease financing or working capital financing activities entered
into in the ordinary course of business or (E) any shares of Common Stock or other rights to acquire capital stock of the Company issued in connection with the acquisition of complementary businesses or technologies by merger or acquisition or in
connection with partnering, license or similar transactions, so long as each person or entity acquiring shares of Common Stock or any securities convertible into or exchangeable into shares of Common Stock agrees to be bound by the terms of this
paragraph. 
  
 3. Terms of Offering. You have advised the
Company that the Initial Purchaser will make an offering of the Securities purchased by the Initial Purchaser hereunder on the terms to be set forth in the Memorandum, as soon as practicable after this Agreement is entered into as in your judgment
is advisable. 
  

 8 

 4. Payment and Delivery. Payment for the Firm Securities shall be made to the Company in Federal
or other funds immediately available in New York City against delivery of such Firm Securities for the account of the Initial Purchaser at 10:00 a.m., New York City time, on June 18, 2003, or at such other time on the same or such other date, not
later than June 24, 2003, as shall be designated in writing by you. The time and date of such payment are hereinafter referred to as the “Closing Date.” 
  
 Payment for any Additional Securities shall be made to the Company in Federal or other funds immediately available in New
York City against delivery of such Additional Securities for the account of the Initial Purchaser at 10:00 a.m., New York City time, on the date specified in the corresponding notice described in Section 2 or at such other time on the same or on
such other date, in any event not later than July 12, 2003, as shall be designated in writing by you. The time and date of such payment is hereinafter referred to as the “Option Closing Date”. 
  
 The Securities shall be in definitive form or global form, as specified by
you, and registered in such names and in such denominations as you shall request in writing not later than one full business day prior to the Closing Date or the applicable Option Closing Date, as the case may be. The Securities shall be delivered
to you on the Closing Date or an Option Closing Date, as the case may be, for the account of the Initial Purchaser, with any transfer taxes payable in connection with the transfer of the Securities to the Initial Purchaser duly paid, against payment
of the Purchase Price therefor plus accrued interest, if any, to the date of payment and delivery. 
  
 5. Conditions to the Initial Purchaser’s Obligation. The obligation of the Initial Purchaser to purchase and pay for the Firm Securities on
the Closing Date are subject to the following conditions: 
  
 (a) Subsequent to the execution and delivery of this Agreement and prior to the Closing Date: 
  
 (i) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any
review for a possible change that does not indicate the direction of the possible change, in the rating accorded the Company or any of the Company’s securities or in the rating outlook for the Company by any “nationally recognized
statistical rating organization,” as such term is defined for purposes of Rule 436(g)(2) under the Securities Act; and 
  
 (ii) there shall not have occurred any change, or any development involving a prospective change, in the condition, financial or
otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken as a whole, from that set forth in the Memorandum provided to prospective purchasers of the Securities that, in your judgment, is material and adverse
and that makes it, in your judgment, impracticable to market the Securities on the terms and in the manner contemplated in the Memorandum. 
  

 9 

 (b) The Initial Purchaser shall have received on the Closing Date a certificate, dated
the Closing Date and signed by an executive officer of the Company, to the effect set forth in Section 5(a)(i) and to the effect that the representations and warranties of the Company contained in this Agreement are true and correct as of the
Closing Date and that the Company has complied in all material respects with all of the agreements and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date. 
  
 The officer signing and delivering such certificate may rely
upon the best of his or her knowledge as to proceedings threatened. 
  
 (c) The Initial Purchaser shall have received on the Closing Date an opinion of Venture Law Group, A Professional Corporation, outside counsel for the Company dated the Closing Date, to the effect set forth in Exhibit
A-1. Such opinion shall be rendered to the Initial Purchaser at the request of the Company and shall so state therein. 
  
 (d) The Initial Purchaser shall have received on the Closing Date an opinion of Davis Polk & Wardwell, counsel for the Initial
Purchaser, dated the Closing Date, to the effect set forth in Exhibit B. 
  
 (e) The Initial Purchaser shall have received on the Closing Date a letter, dated the Closing Date, in form and substance satisfactory to the Initial Purchaser, from Ernst & Young LLP, independent public
accountants, containing statements and information of the type ordinarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained in or
incorporated by reference into the Memorandum; provided that the letter shall use a “cut-off date” not earlier than the date hereof. 
  
 (f) The “lock-up” agreements, each substantially in the form of Exhibit C hereto, between you and the executive officers and
directors of the Company relating to sales and certain other dispositions of shares of common stock or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date. 
  
 The obligation of the Initial Purchaser to purchase Additional Securities
hereunder is subject to the delivery to you on the applicable Option Closing Date of such documents as you may reasonably request with respect to the good standing of the Company, the due authorization, execution and authentication of the Additional
Securities to be sold on such Option Closing Date and other matters related to the execution and authentication of such Additional Securities. 
  
 6. Covenants of the Company. In further consideration of the agreements of the Initial Purchaser contained in this Agreement, the Company covenants
with the Initial Purchaser as follows: 
  

 10 

 (a) To furnish to you in New York City, without charge, prior to 10:00 a.m. New York City
time on the business day next succeeding the date of this Agreement and during the period mentioned in Section 6(c), as many copies of the Memorandum, any documents incorporated by reference therein and any supplements and amendments thereto as you
may reasonably request. 
  
 (b) Before amending
or supplementing the Memorandum, to furnish to you a copy of each such proposed amendment or supplement and not to use any such proposed amendment or supplement to which you reasonably object. 
  
 (c) If, during such period after the date hereof and prior
to the date on which all of the Securities shall have been sold by the Initial Purchaser, any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Memorandum in order to make the statements therein, in
the light of the circumstances when the Memorandum is delivered to a purchaser, not misleading, or if, in the opinion of counsel for the Initial Purchaser, it is necessary to amend or supplement the Memorandum to comply with applicable law,
forthwith to prepare and furnish, at its own expense, to the Initial Purchaser, either amendments or supplements to the Memorandum so that the statements in the Memorandum as so amended or supplemented will not, in the light of the circumstances
when the Memorandum is delivered to a purchaser, be misleading or so that the Memorandum, as amended or supplemented, will comply with applicable law. 
  
 (d) To endeavor to qualify the Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions as you shall
reasonably request; provided, however, that the Company will not be required to qualify to do business in any jurisdiction in which it is not then so qualified, to file any general consent to service of process or to take any other action that would
subject it to general service of process or to taxation in any such jurisdiction where it is not then so subject. 
  
 (e) Whether or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, to pay or cause to be
paid all expenses, if any, incident to the performance of its obligations under this Agreement, including: (i) the fees, disbursements and expenses of the Company’s counsel and the Company’s accountants in connection with the issuance and
sale of the Securities and all other fees or expenses in connection with the preparation of the Memorandum and all amendments and supplements thereto, including all printing costs associated therewith, and the delivering of copies thereof to the
Initial Purchaser, in the quantities herein above specified, (ii) all costs and expenses related to the transfer and delivery of the Securities to the Initial Purchaser, including any transfer or other taxes payable thereon, (iii) the cost of
printing or producing any Blue Sky memorandum in connection with the offer and sale of the Securities under state securities laws and all expenses in connection with the qualification of the Securities for offer and sale under state securities laws
as provided in Section 6(d) hereof, including filing fees and the reasonable fees and disbursements of counsel for the Initial Purchaser in connection with such qualification and in connection with the Blue 
  

 11 

 
Sky memorandum, (iv) any fees charged by rating agencies for the rating of the Securities, if any, (v) the fees and expenses, if any, incurred in connection
with the admission of the Securities for trading in PORTAL or any appropriate market system, (vi) the costs and charges of the Trustee and any transfer agent, registrar or depositary, (vii) the cost of the preparation, issuance and delivery of the
Securities, (viii) the document production charges and expenses associated with printing this Agreement and (ix) all other cost and expenses incident to the performance of the obligations of the Company hereunder for which provision is not otherwise
made in this Section. It is understood, however, that except as provided in this Section, Section 8, and the last paragraph of Section 10, the Initial Purchaser will pay all of its costs and expenses, including fees and disbursements of its counsel,
transfer taxes payable on resale of any of the Securities by it and any advertising expenses connected with any offers it may make. 
  
 (f) Neither the Company nor any Affiliate will sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any
security (as defined in the Securities Act) which could be integrated with the sale of the Securities in a manner which would require the registration under the Securities Act of the Securities. 
  
 (g) Not to solicit any offer to buy, or offer or sell, the
Securities or the Underlying Securities by means of any form of general solicitation or general advertising (as those terms are used in Regulation D under the Securities Act) or in any manner involving a public offering within the meaning of Section
4(2) of the Securities Act. 
  
 (h) While any of
the Securities or the Underlying Securities remain “restricted securities” within the meaning of the Securities Act, to make available, upon request, to any seller of such Securities the information specified in Rule 144A(d)(4) under the
Securities Act, unless the Company is then subject to Section 13 or 15(d) of the Exchange Act. 
  
 (i) If requested by you, to use its reasonable best efforts to permit the Securities to be designated PORTAL securities in accordance with
the rules and regulations adopted by the National Association of Securities Dealers, Inc. relating to trading in the PORTAL Market. 
  
 (j) During the period of two years after the Closing Date or any Option Closing Date, if later, the Company will not, and will not permit
any of its affiliates (as defined in Rule 144 under the Securities Act) to resell any of the Securities or the Underlying Securities which constitute “restricted securities” under Rule 144 that have been reacquired by any of them;
provided, however, that this covenant shall not apply to any of the Securities or the Underlying Securities that have previously been sold pursuant to an effective Registration Statement or under Rule 144. 
  
 (k) Not to take any action prohibited by Regulation M under
the Exchange Act in connection with the distribution of the Securities contemplated hereby. 
  

 12 

 7. Offering of Securities; Restrictions on Transfer. (a) The Initial Purchaser represents and
warrants that it is a qualified institutional buyer as defined in Rule 144A under the Securities Act (a “QIB”). The Initial Purchaser, agrees with the Company that (i) it will not solicit offers for, or offer or sell, such
Securities by any form of general solicitation or general advertising (as those terms are used in Regulation D under the Securities Act) or in any manner involving a public offering within the meaning of Section 4(2) of the Securities Act and (ii)
it will solicit offers for such Securities only from, and will offer such Securities only to, persons that it reasonably believes to be QIBs that in purchasing such Securities are deemed to have represented and agreed as provided in the Memorandum
under the caption “Transfer Restrictions”. 
  
 8.
Indemnity and Contribution. (a) The Company agrees to indemnify and hold harmless the Initial Purchaser, each person, if any, who controls the Initial Purchaser within the meaning of either Section 15 of the Securities Act or Section 20 of
the Exchange Act, and each affiliate of the Initial Purchaser within the meaning of Rule 405 under the Securities Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal or other expenses
reasonably incurred in connection with defending or investigating any such action or claim) caused by any untrue statement or alleged untrue statement of a material fact contained in the Memorandum (as amended or supplemented if the Company shall
have furnished any amendments or supplements thereto), or caused by any omission or alleged omission to state therein a material fact necessary to make the statements therein in the light of the circumstances under which they were made not
misleading, except insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission or alleged untrue statement or omission based upon information relating to the Initial Purchaser furnished to the Company
in writing by the Initial Purchaser expressly for use therein; provided that the foregoing indemnity shall not inure to the benefit of the Initial Purchaser from whom the person asserting any such loss, claims, damages or liabilities purchased
Securities or Underlying Securities, or any person controlling the Initial Purchaser, if a copy of the Memorandum (as then amended or supplemented if the Company shall have furnished any amendments or supplements thereto) was not sent or given by or
on behalf of the Initial Purchaser to such person, if required by law to have been so delivered, at or prior to the written confirmation of the sale of the Securities or Underlying Securities to such person, and if the Memorandum (as so amended or
supplemented) would have cured the defect giving rise to such losses, claims, damages or liabilities, unless such failure is the result of noncompliance by the Company with Section 6(a) hereof. 
  
 (b) The Initial Purchaser agrees to indemnify and hold harmless the Company,
its directors, its officers and each person, if any, who controls the Company within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the foregoing indemnity from the Company to the
Initial Purchaser, but only with reference to information relating to such Initial Purchaser furnished to the Company in writing by the Initial Purchaser expressly for use in the Memorandum or any amendments or supplements thereto. 
  
 (c) In case any proceeding (including any governmental investigation) shall
be instituted involving any person in respect of which indemnity may be sought pursuant to Section 
  

 13 

 
8(a) or 8(b), such person (the “indemnified party”) shall promptly notify the person against whom such indemnity may be sought (the
“indemnifying party”) in writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the
indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and
expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel or (ii) the named parties to any such proceeding
(including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is
understood that the indemnifying party shall not, in respect of the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one
separate firm (in addition to any local counsel at its standard non-premium rates) for all such indemnified parties and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing by Morgan
Stanley & Co. Incorporated, in the case of parties indemnified pursuant to Section 8(a), and by the Company, in the case of parties indemnified pursuant to Section 8(b). The indemnifying party shall not be liable for any settlement of any
proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of
such settlement or judgment that is indemnifiable pursuant to Section 8(a) or 8(b), as the case may be. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened
proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified party from all
liability on claims that are the subject matter of such proceeding. 
  
 (d) To the extent the indemnification provided for in Section 8(a) or 8(b) is unavailable to an indemnified party or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party
under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (i) in such proportion as is
appropriate to reflect the relative benefits received by the Company on the one hand and the Initial Purchaser on the other hand from the offering of the Securities or (ii) if the allocation provided by clause 8(d)(i) above is not permitted by
applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause 8(d)(i) above but also the relative fault of the Company on the one hand and of the Initial Purchaser on the other hand in
connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Initial Purchaser
on the other hand in connection with the offering of the Securities shall be deemed to be in the same respective proportions as the net proceeds from the offering of the Securities (before deducting expenses) received by the 
  

 14 

 
Company and the total discounts and commissions received by the Initial Purchaser bear to the aggregate offering price of the Securities. The relative fault
of the Company on the one hand and of the Initial Purchaser on the other hand shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by the Company or by the Initial Purchaser and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 
  
 (e) The Company and the Initial Purchaser agree that it would not be just or
equitable if contribution pursuant to this Section 8(d) were determined by pro rata allocation or by any other method of allocation that does not take account of the equitable considerations referred to in Section 8(d). The amount paid or
payable by an indemnified party as a result of the losses, claims, damages and liabilities referred to in Section 8(d) shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such
indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 8, the Initial Purchaser shall not be required to contribute any amount in excess of the amount by which the
total price at which the Securities resold by it in the initial placement of such Securities were offered to investors exceeds the amount of any damages that the Initial Purchaser has otherwise been required to pay by reason of such untrue or
alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such
fraudulent misrepresentation. The remedies provided for in this Section 8 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any indemnified party at law or in equity. 
  
 (f) The indemnity and contribution provisions contained in this Section 8 and
the representations, warranties and other statements of the Company and the Initial Purchaser contained in this Agreement shall remain operative and in full force and effect regardless of (i) any termination of this Agreement, (ii) any investigation
made by or on behalf of the Initial Purchaser, any person controlling the Initial Purchaser or any affiliate of the Initial Purchaser or by or on behalf of the Company, its officers or directors or any person controlling the Company and (iii)
acceptance of and payment for any of the Securities. 
  
 9.
Termination. The Initial Purchaser may terminate this Agreement by notice given to the Company, if after the execution and delivery of this Agreement and prior to the Closing Date (i) trading generally shall have been suspended or materially
limited on, or by, as the case may be, any of the New York Stock Exchange, the American Stock Exchange, the Nasdaq National Market, the Chicago Board of Options Exchange, the Chicago Mercantile Exchange or the Chicago Board of Trade, (ii) trading of
any securities of the Company shall have been suspended on any exchange or in any over-the-counter market, (iii) a material disruption in securities settlement, payment or clearance services in the United States shall have occurred, (iv) any
moratorium on commercial banking activities shall have been declared by Federal or New York State authorities or (v) there shall have occurred any outbreak or escalation of hostilities, or any change in financial markets or any calamity or crisis
that, in your judgment, is material and adverse and which, singly or together with any other event specified in this clause (v), makes it, 
  

 15 

 
in your judgment, impracticable or inadvisable to proceed with the offer, sale or delivery of the Securities on the terms and in the manner contemplated in
the Memorandum. 
  
 10. Effectiveness. This Agreement shall
become effective upon the execution and delivery hereof by the parties hereto. 
  
 If this Agreement shall be terminated by the Initial Purchaser because of any failure or refusal on the part of the Company to comply with the terms or to fulfill any of the conditions of this Agreement, or if for any
reason the Company shall be unable to perform its obligations under this Agreement, the Company will reimburse the Initial Purchaser for all out-of-pocket expenses (including the fees and disbursements of their counsel) reasonably incurred by the
Initial Purchaser in connection with this Agreement or the offering contemplated hereunder. 
  
 11. Counterparts. This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.

  
 12. Applicable Law. This Agreement shall be governed by
and construed in accordance with the internal laws of the State of New York. 
  
 13. Headings. The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be deemed a part of this Agreement. 
  

 16 

	 Very truly yours,

	
	 DURECT CORPORATION

		
	 By:
	 	 /s/ Thomas A. Schreck

	 	 	 Name:  Thomas A. Schreck

	 	 	 Title:    Chief Financial Officer

  

 17 

 Accepted as of the date hereof 
  
 Morgan Stanley & Co. Incorporated 
  

	 By:
	 	 /s/ Bryan W. Andrzejewski

	 	 	 Name:  Bryan W. Andrzejewski

	 	 	 Title:    Executive Director

  

 18 

 EXHIBIT A-1 
  

OPINION OF VENTURE LAW GROUP, A PROFESSIONAL CORPORATION 
  

The opinion of Venture Law Group, A Professional Corporation, to be delivered pursuant to Section 5(c) of the Purchase Agreement shall be to the effect
that: 
  
 A. The Company is validly existing as a corporation in
good standing under the laws of the State of Delaware. 
  
 B. The
Company has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Memorandum and to enter into and perform its obligations under each of the Purchase Agreement, the Registration
Rights Agreement, the Indenture and the Securities. 
  
 C. The
shares of common stock of the Company issuable upon conversion of the Securities have been duly authorized and, when issued in accordance with the terms of the Indenture, will be validly issued, fully paid and nonassessable. 
  
 D. The Purchase Agreement has been duly authorized, executed and delivered
by, and is a valid and binding agreement of, the Company, enforceable against the Company in accordance with its terms, except as the enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws
relating to or affecting the rights and remedies of creditors or by general equitable principles and except as rights to indemnification may be limited by applicable law or public policy. 
  
 E. The Registration Rights Agreement has been duly authorized, executed and delivered by, and is a valid and binding
agreement of, the Company, enforceable in accordance with its terms, except as the enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of
creditors or by general equitable principles and except as rights to indemnification may be limited by applicable law or public policy. 
  
 F. The Indenture has been duly authorized, executed and delivered by, and is a valid and binding agreement of, the Company, enforceable against the
Company in accordance with its terms, except as the enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable
principles. 
  
 G. The Securities are in the form contemplated by
the Indenture, have been duly authorized by the Company for issuance and sale pursuant to the Purchase Agreement and the Indenture and, when executed by the Company and authenticated by the Trustee in the manner provided in the Indenture, and
delivered against payment of the purchase price therefor, will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy,

 
insolvency, reorganization, moratorium or other similar laws relating to or affecting enforcement of the rights and remedies of creditors or by general
equitable principles. 
  
 H. The statements in the Memorandum
under the captions “Description of the Notes” and “U.S. Federal Income Tax Considerations” (insofar as such statements constitute matters of law), summaries of legal matters, the charter or by-law provisions of the Company,
documents or legal proceedings, or legal conclusions, have been reviewed by us and fairly present and summarize, in all material respects, the matters referred to therein. 
  
 I. No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or
regulatory authority or agency is required for the Company’s execution, delivery and performance of the Purchase Agreement, the Registration Rights Agreement or the Indenture, or the issuance and delivery of the Securities, or consummation of
the transactions contemplated thereby, except such as have been obtained or may be made by the Company after the Closing Date under the Securities Act, except such as may be required under applicable state securities or blue sky laws, and except
such as may be required by federal and state securities laws with respect to the Company’s obligations under the Registration Rights Agreement. 
  
 J. The execution and delivery of the Purchase Agreement, the Registration Rights Agreement, the Securities and the Indenture by the Company and the
performance by the Company of its obligations thereunder, and consummation of the transactions contemplated thereby: (i) will not result in any violation of the provisions of the charter or by-laws of the Company; (ii) will not conflict with or
constitute a breach of any material contract (a) filed as an exhibit to the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2002, (b) filed as an exhibit to the Company’s most recent Quarterly Report on
form 10-Q for the three months ended March 31, 2003, or (c) entered into after March 31, 2003, except for such conflicts or breaches as would not, individually or in the aggregate, have a material adverse effect on the Company and its subsidiaries,
taken as a whole; and (iii) will not result in any violation of any law, administrative regulation or administrative or court decree known to us applicable to the Company or any of its subsidiaries. 
  
 K. The Company is not, and after receipt of payment for the Securities will
not be, an “investment company” within the meaning of the Investment Company Act. 
  
 L. To our knowledge, there is no pending or threatened action, suit or proceeding before any court or governmental agency, authority or body involving the Company except for actions, suits or proceedings which are
either disclosed in the Memorandum or, if not so disclosed, would not, individually or in the aggregate with all such other actions, suits and proceedings, have, if adversely determined, a material adverse effect on the Company and its subsidiaries,
taken as a whole. 
  
 M. Assuming the accuracy of the
representations, warranties and covenants of the Company and the Initial Purchaser contained in the Purchase Agreement, no registration of the Securities under the Securities Act, and no qualification of an indenture under the Trust 
  

 2 

 
Indenture Act with respect thereto, is required in connection with the purchase of the Securities by the Initial Purchaser or the initial resale of the
Securities by the Initial Purchaser to QIBs in the manner contemplated by the Purchase Agreement and the Memorandum other than any registration or qualification that may be required in connection with the Registration Rights Agreement. 

 
 N. Nothing has come to our attention which would lead us to believe that
the Memorandum, as of its date or at the Closing Date, contained or contains an untrue statement of a material fact or omitted or omits to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading (it being understood that we express no statement of belief as to the financial statements and schedules or other financial and statistical data derived therefrom, included or incorporated by reference in
the Memorandum). 
  
 With respect to the matters referred to in
paragraph N above, counsel may state that his or her beliefs are based upon his or her participation in the preparation of the Memorandum (and any amendments or supplements thereto) and review and discussion of the contents thereof and review of the
documents incorporated by reference therein, but are without independent check or verification except as specified. 
  
 O. Nothing has come to our attention which would lead us to believe that each document incorporated by reference in the Memorandum did not comply as to
form when filed with the Commission in all material respects with the Exchange Act and the rules and regulations of the Commission thereunder (it being understood that we express no statement of belief as to the financial statements and schedules or
other financial and statistical data derived therefrom, included or incorporated by reference therein). 
  
 With respect to the matters referred to in paragraph O above, counsel may state that his or her beliefs are based upon his or her participation in the
preparation of the Memorandum (and any amendments or supplements thereto) and review and discussion of the contents thereof and review of the documents incorporated by reference therein, but are without independent check or verification except as
specified. 
  
 P. The Company is duly qualified to transact
business and is in good standing in California. 
  
 Q. The
authorized capital stock of the Company conforms as to legal matters to the description thereof contained in the Memorandum. 
  

 3 

 EXHIBIT B 
  

OPINION OF DAVIS POLK & WARDWELL 
  
 The opinion of Davis Polk & Wardwell to be delivered pursuant to Section 5(d) of the Purchase Agreement shall be to the effect that: 
  
 A. The Purchase Agreement has been duly authorized, executed and delivered
by the Company. 
  
 B. The Securities have been duly authorized by
the Company and, when executed and authenticated in accordance with the provisions of the Indenture and delivered to and paid for by the Initial Purchaser in accordance with the terms of the Purchase Agreement, will be valid and binding obligations
of the Company, enforceable in accordance with their terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and equitable principles of general applicability, and will be entitled to the
benefits of the Indenture and the Registration Rights Agreement pursuant to which such Securities are to be issued. 
  
 C. The Underlying Securities issuable upon conversion of the Securities have been duly authorized and reserved and, when issued upon conversion of the
Securities in accordance with the terms of the Securities, will be validly issued, fully paid and non-assessable, and the issuance of the Underlying Securities will not be subject to any preemptive or similar rights. 
  
 D. Each of the Indenture and the Registration Rights Agreement has been duly
authorized, executed and delivered by, and is a valid and binding agreement of, the Company, enforceable in accordance with its terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and
equitable principles of general applicability, and except as rights to indemnification and contribution under the Registration Rights Agreement may be limited under applicable law. 
  
 E. The statements relating to legal matters or documents included in the Memorandum under the captions “Description of
Notes”, “Plan of Distribution” and “Transfer Restrictions”, fairly summarize in all material respects such matters or documents. 
  
 F. Nothing has come to the attention of such counsel to cause such counsel to believe that (except for the financial statements and financial schedules
and other financial and statistical data, as to which such counsel need not express any belief) the Memorandum when issued contained, or as of the date such opinion is delivered contains, any untrue statement of a material fact or omitted or omits
to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. 
  
 With respect to the matters referred to in the paragraph above, Davis Polk & Wardwell may state that their beliefs are based upon their participation
in the preparation of the Memorandum (and any amendments or supplements thereto) and review and discussion of the 

 
contents thereof (including the review of, but not participation in the preparation of, the incorporated documents), but are without independent check or
verification except as specified. 
  
 G. Based upon the
representations, warranties and agreements of the Company in Sections 1(r), 1(t), 6(f) and 6(g) of the Purchase Agreement and of the Initial Purchaser in Section 7 of the Purchase Agreement, it is not necessary in connection with the offer, sale and
delivery of the Securities to the Initial Purchaser under the Purchase Agreement or in connection with the initial resale of such Securities by the Initial Purchaser in accordance with Section 7 of the Purchase Agreement to register the Securities
under the Securities Act of 1933 or to qualify the Indenture under the Trust Indenture Act of 1939, it being understood that no opinion is expressed as to any subsequent resale of any Security or Underlying Security. 
  

 2 

 EXHIBIT C 
  

FORM OF LOCK-UP LETTER 
  
 June 12, 2003 
  
 Morgan Stanley & Co. Incorporated 
 1585 Broadway 
 New York, NY 10036 
  
 Dear Sirs and Mesdames: 
  
 The undersigned understands that Morgan Stanley & Co. Incorporated (“Morgan Stanley”) proposes to enter
into a Purchase Agreement (the “Purchase Agreement”) with DURECT Corporation, a Delaware corporation (the “Company”), providing for the offering (the “Offering”) by Morgan Stanley of securities (the
“Securities”) convertible into shares of common stock, $0.0001 par value of the Company (the “Common Stock”). 
  
 To induce Morgan Stanley to continue its efforts in connection with the Offering, the undersigned hereby agrees that, without the prior written consent of
Morgan Stanley, it will not, during the period commencing on the date hereof and ending 90 days after the date of the final offering memorandum relating to the Offering (the “Final Memorandum”), (1) offer, pledge, sell, contract to
sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock or (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such
transaction described in clause (1) or (2) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise. The foregoing sentence shall not apply to (a) the sale of any Securities to Morgan Stanley pursuant to the
Purchase Agreement or (b) transactions relating to shares of Common Stock or other securities acquired in open market transactions after the completion of the Offering. The undersigned agrees to suspend, or terminate, any plan pursuant to Rule
10b5-1 under the Securities Exchange Act of 1934, as amended, under which sales or other transfers of Common Stock could occur during the period described above. In addition, the undersigned agrees that, without the prior written consent of Morgan
Stanley, it will not, during the period commencing on the date hereof and ending 90 days after the date of the Final Memorandum, make any demand for or exercise any right with respect to, the registration of any shares of Common Stock 

 
or any security convertible into or exercisable or exchangeable for Common Stock. The undersigned also agrees and consents to the entry of stop transfer
instructions with the Company’s transfer agent and registrar against the transfer of the undersigned’s shares of Common Stock except in compliance with the foregoing restrictions. 
  
 The undersigned understands that the Company and Morgan Stanley are relying
upon this Lock-Up Agreement in proceeding toward consummation of the Offering. The undersigned further understands that this Lock-Up Agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives, successors
and assigns. 
  
 Whether or not the Offering actually occurs
depends on a number of factors, including market conditions. Any Offering will only be made pursuant to a Purchase Agreement, the terms of which are subject to negotiation between the Company and Morgan Stanley. 
  
 This Lock-Up Agreement will terminate automatically in the event the Offering
is not consummated prior to June 25, 2003. 
  

	 Very truly yours,

	
	

	 (Name)

	
	

	 (Address)

  

 2AMENDED AND RESTATED DIRECTOR COMPENSATION METHOD PLAN

 Exhibit 4.4 
  

 
 CYTYC CORPORATION 
  
 AMENDED AND RESTATED 
 DIRECTOR COMPENSATION METHOD PLAN 
  
  

	1.	 	Purpose. Cytyc Corporation, a Delaware corporation (the “Company”), hereby adopts this Director Compensation Method Plan (the “DCM Plan”) to
promote the long-term growth and financial success of the Company by attracting and retaining non-employee directors of outstanding ability and promoting a greater identity of interest between the Company’s non-employee directors and its
stockholders. 

  

	2.	 	Administration. 

  

	 	2.1	 	The DCM Plan shall be administered by a committee (the “DCM Committee”) appointed by the Board of Directors of the Company (the “Board”) consisting of the then
current Chairman of the Compensation Committee of the Board and the Secretary of the Company. The DCM Committee may be changed at any time in the discretion of the Board. 

  

	 	2.2	 	The DCM Committee shall have the authority (i) to exercise all of the powers granted to it under the DCM Plan, (ii) to construe, interpret and implement the DCM Plan and all
relevant documents, (iii) to prescribe, amend and rescind rules relating to the DCM Plan, and (iv) to make any determination necessary or advisable in administering the DCM Plan. 

  

	 	2.3	 	The determination of the DCM Committee on all matters relating to the DCM Plan, or any document executed pursuant to the DCM Plan, shall be conclusive. 

  

	 	2.4	 	No member of the DCM Committee shall be liable for any action or determination made in good faith with respect to the DCM Plan. 

  

	3.	 	Eligibility. Only non-employee directors of the Company or any affiliate of the Company (“Eligible Directors”) shall participate in the DCM Plan.

  

	4.	 	Common Shares Subject to the DCM Plan. 

  

	 	4.1	 	Shares. For purposes of the DCM Plan, “Shares” shall mean shares of common stock, par value $.01 per share, of the Company and any other stock into which such
common stock shall thereafter be changed by reason of any merger, reorganization, recapitalization, consolidation, split-up, combination of shares or similar event as set forth in and in accordance with this Section 4. 

	 	4.2	 	Shares Available for Awards. Subject to Section 4.3 (relating to adjustments upon changes in capitalization), as of any date, the total number of Shares issuable under the
DCM Plan shall be issued from the shares authorized for issuance pursuant to the Company’s 2001 Non-Employee Director Stock Plan, including any successor plan. 

  

	 	4.3	 	Adjustments. Adjustments to the Shares shall be made in accordance with Section 3(b) of the Company’s 2001 Non-Employee Director Stock Plan, including the applicable
provision of any successor plan. 

  

	5.	 	Payment of Retainer, Meeting Fees and Service Awards. 

  

	 	5.1	 	In General. Commencing on the DCM Plan Effective Date (as herein defined), each Eligible Director may elect to receive payment of the annual retainer payable to such Director
for services as a member of the Board and its committees (the “Retainer”) in cash or in Shares (provided, however, that the Board may determine that a portion of the annual retainer will be paid as Shares). Fees payable to such Director
for meetings of the Board or committees of the Board (the “Meeting Fees”) shall be paid in cash, and any other service related grant of shares to a Director, approved by the Board from time to time, shall be paid in Shares (the
“Service Award” and together with the “Retainer” and “Meeting Fees” collectively, “Director Compensation”). Each Eligible Director may elect to receive Director Compensation currently in accordance with the
provisions of Section 5.2 (the “Current Payment Election”) or to defer Director Compensation (the “Deferred Payment Election”) in accordance with the provisions of Section 5.3. In the absence of an election, all payments to the
Eligible Directors of the Retainer and the Meeting Fees shall be paid currently in cash and the Service Award, if any, shall be paid currently in Shares. 

  

	 	5.2	 	Election to Receive the Retainer in Shares Without Deferral. An Eligible Director may elect, with respect to any calendar year, to receive payment of the Retainer due for
such calendar year in Shares (the “Current Payment Election”), valued at their Fair Market Value on the date on which such amounts become payable, by submitting an election form (“Current Payment Election Form”) to the Company
within 30 days after the DCM Plan Effective Date, or for subsequent calendar years, at least 30 days prior to the beginning of any calendar year. Except as provided herein, the beginning of such calendar year shall be the effective date of such
election for payment of such Retainer. A Current Payment Election shall be effective only with respect to the Retainer that become payable after the effective date. Any election made under this Section 5.2 shall continue in full force and effect,
including for subsequent calendar years, until revoked by written notice to the Company, until superseded by a new Current Payment Election Form, or unless no longer permitted by law or regulations. 

	 	5.3	 	Elective Deferrals. An Eligible Director may elect to defer the payment of some or all of the Director Compensation (the “Deferred Amount”) by submitting an
election form (a “Deferred Payment Election Form”) to the Company at least 30 days prior to any calendar year in which such Director Compensation would otherwise be paid to the Eligible Director. Except as provided herein, any such
election shall become effective for the calendar year following the calendar year in which such Deferred Payment Election Form is submitted to the Company. An election under this Section 5.3 shall continue in effect, until the end of the calendar
year in which it is revoked by written notice to the Company, until it is superseded by a new Deferred Payment Election Form, or immediately, if no longer permitted by law or regulation. 

  
 Notwithstanding the foregoing, (i) all Meeting Fees relating to the July 23,
2003 Board meeting will be paid in current cash and (ii) Eligible Directors who elected to receive their Meeting Fees for calendar year 2003 as shares shall be eligible to make a special election, which election shall be made no later than 30 days
prior to the Board meeting occurring after the July 23, 2003 Board meeting, to receive the balance of their Meeting Fees for calendar year 2003 as current or deferred cash. In addition, if an Eligible Director filed a Deferred Payment Election Form
under this Section 5.3 deferring the payment of Shares earned in the calendar year 2003, such election form shall be deemed to require the deferral of all of such Eligible Director’s Director Compensation for calendar year 2003 that consists of
Shares. 
  
 An Eligible Director may designate, in a Deferred
Payment Election Form, one or more beneficiaries to receive any distributions under the DCM Plan upon the death of the Eligible Director, and such designation may be changed at any time by submitting a new designation in writing to the Company,
which shall become effective immediately upon receipt by the Company. If no beneficiary is designated by an Eligible Director, distributions under the DCM Plan shall be made to the Eligible Director’s estate. 
  

	 	(a)	 	Cash Account: The Deferred Payment Election Form shall indicate: (i) any Retainer or Meeting Fees to be allocated to the “Cash Account” (the “Deferred
Amount”); and (ii) the date on which the commencement of payments of Deferred Amounts (the “Distribution Date”) should begin, as contemplated by Section 5.4(a). 

  

	 	(b)	 	Share Account: The Deferred Payment Election Form shall indicate: any Retainer or Service Awards to be credited to an account (a “Share Account”) in units which are
equivalent in value to Shares (“Share Units”) which shall comprise the “Deferred Amount”. The Deferred Amount allocated to the Share Account shall be credited to the Share Account no later than the end of the month during which
the Eligible Director becomes entitled to payment of the Retainer and/or the Service Award. The number of Share Units credited to such Share Account shall be an 

  

 amount equal to the sum of (a) the number of Shares granted under the Service Award and (b) the result
obtained by dividing (i) the amount of the deferred Retainer allocated to the Share Account by (ii) the Fair Market Value of a Share on the business day on which the Eligible Director becomes entitled to payment of the Retainer. If Share Units exist
in an Eligible Director’s Share Account on a dividend record date for the Company’s Shares, the Share Account shall be credited, on the dividend payment date, with an additional number of Share Units equal to (x) the cash dividend paid on
one Share, times (y) the number of Share Units in the Share Account on the dividend record date, divided by (z) the Fair Market Value of a Share on the dividend payment date. 
  

	 	5.4	 	Distributions. 

  

	 	(a)	 	Distribution Date. Each Eligible Director shall designate, on a Deferred Payment Election Form, one of the following dates as a Distribution Date with respect to the Deferred
Amount credited to the Eligible Director’s Account thereafter: (i) the first day of a month following the termination of service or retirement of the Eligible Director as a member of the Board, (ii) a fixed date in the future at least one year
after the date of such deferral as specified on a Deferred Payment Election Form or (iii) the earlier to occur of (i) or (ii). In the event of an Eligible Director’s death, all Deferred Amounts shall be paid no later than the end of the month
following the occurrence of such event. 

  

	 	(b)	 	Share Account Distribution Method. Distributions shall be made from the Eligible Director’s Share Account in a single payment in the form of whole Shares, and cash
representing any fractional interest in a Share. 

  

	 	(c)	 	Emergency Distribution. In the event that an Eligible Director encounters an unanticipated emergency that is caused by an event beyond the control of such Eligible Director
and/or his/her beneficiary (if any) which would result in severe financial hardship if early withdrawal were not permitted, the Eligible Director may submit a written request to the DCM Committee outlining the nature of such emergency and the
portion of any Deferred Amount (the “Early Distribution”) necessary to meet such emergency. The DCM Committee, in its sole discretion, shall determine the amount of any such Early Distribution to be paid in accordance with the terms of
this Section 5.4. 

  

	 	5.5	 	Interest on Cash Deferrals. Any payments due an Eligible Director and deferred into the Cash Account shall be credited as of January 1, April 1, July 1 and October 1 of each
year, with an amount equal to the balance in said account at the end of the preceding quarter, multiplied by the percentage that represents 25% of the prime rate of interest as reflected in the Wall Street Journal on the last business day of the
preceding quarter. 

	6.	 	Definition of Fair Market Value. For purposes of this DCM Plan, in respect to the valuation of Shares, if the Company’s Common Stock is publicly traded, Fair
Market Value” shall be determined as of the last business day for which prices or quotes are available and shall mean (a) the average (on that date) of the high and low prices of the Common Stock on the principal national securities exchange on
which the Common Stock is traded, if the Common Stock is then traded on a national securities exchange; or (b) the last reported sale price (on that date) of the Common Stock on the Nasdaq Stock Market, if the Common Stock is not then traded on a
national securities exchange; or (c) the closing bid price (or average of bid prices) last quoted (on that date) by an established quotation service for over-the-counter securities, if the Common Stock is not reported on the Nasdaq Stock market.
However, if the Common Stock is not publicly traded at the time a Share is to be credited to a Share Account under the DCM Plan, “Fair Market Value” shall be deemed to be the fair value of the Common Stock as determined by the DCM
Committee after taking into consideration all factors which it deems appropriate, including, without limitation, recent sale and offer prices of the Common Stock in private transactions negotiated at arm’s length; provided, however, that the
“Fair Market Value” of the stock issuable upon a Distribution Date pursuant to the DCM Plan within 120 days prior to the time the Company’s Common Stock is publicly traded shall be deemed to be equal to the initial per share purchase
price at which the Company’s Common Stock is offered to the public. 

  

	7.	 	Definition of Disability. “Disability” shall mean any condition which causes an Eligible Director to be unable to substantially perform services as a member
of the Board for a period of at least three consecutive months, or for an aggregate of at least five months within any 12-month period. 

  

	8.	 	Issuance of Certificates and Legal Compliance. 

  

	 	8.1	 	Restrictions on Transferability. All Shares delivered pursuant to an election made under Section 5 of the DCM Plan shall contain such restrictive legends and be subject to
such stop-transfer orders and other restrictions as the Company may deem advisable or legally necessary under any laws, rules, regulations and other legal requirements including, without limitation, those of any stock exchange upon which the Shares
are then listed and any applicable federal, state or foreign securities law. 

  

	 	8.2	 	Compliance with Laws. Anything to the contrary herein notwithstanding, the Company shall not be required to issue any Shares under the DCM Plan if, in the opinion of the
Company’s General Counsel, the issuance and delivery of such Shares would constitute a violation by the Eligible Director or the Company of any applicable law or regulation of any governmental authority, including, without limitation, federal
and state securities laws and the rules of any stock exchange on which the Company’s securities may then be listed. If and to the extent that the DCM Committee determines that it would be illegal, impractical or inadvisable to issue Shares
under the DCM Plan, or to the extent Shares are 

  

 unavailable, the DCM Committee shall make any distribution of Shares otherwise required under the DCM
Plan in cash. 
  

	 	8.3	 	Listing, Registration and Legal Compliance. If the DCM Committee shall at any time determine that any Consent (as hereinafter defined) is necessary or desirable as a
condition of, or in connection with, the DCM Plan, the issuance of Shares or other rights hereunder or the taking of any other action hereunder (each such action being hereinafter referred to as a “Plan Action”), then such Plan Action
shall not be taken, in whole or in part, unless and until such Consent shall have been effected or obtained. The term “Consent” as used herein with respect to any Plan Action means (a) the listing, registration or qualification of any
Shares issued under the DCM Plan on any securities exchange or under any foreign, federal, state or local law, rule or regulation, (b) any and all consents, clearances and approvals in respect of a Plan Action by any governmental or other regulatory
bodies, or (c) any and all written agreements and representations by an Eligible Director with respect to the disposition of Shares or with respect to any other matter which the DCM Committee shall deem necessary or desirable in order to comply with
the terms of any such listing, registration or qualification or to obtain an exemption from the requirement that any such listing, qualification or registration be made. 

  

	 	8.4	 	Governing Law. The DCM Plan shall be governed by, and construed in accordance with, the laws of the Commonwealth of Massachusetts. 

  

	 	8.5	 	Rights as a Shareholder. An Eligible Director shall have no rights as a shareholder of the Company with respect to any Shares issuable under the DCM Plan until such Shares
have been delivered to the Eligible Director. 

  

	9.	 	Tax Related Issues. 

  

	 	9.1	 	Withholding and Other Obligations. The Company shall require as a condition of delivery of any Shares or payment of any Deferred Amount to an Eligible Director that, if
applicable, such Director remit an amount sufficient to satisfy any foreign, federal, state, local and other governmental withholding tax requirements relating thereto and any indebtedness or other obligation of the Eligible Director to the Company.

  

	 	9.2	 	Unfunded DCM Plan. The DCM Plan shall be unfunded and shall not create (or be construed to create) a trust or separate fund. The DCM Plan shall not establish any fiduciary
relationship between the Company and any Eligible Director or other person and shall constitute a mere promise by the Company to make payments in the future. To the extent any person holds any rights by virtue of a pending deferral under the DCM
Plan, such rights shall be no greater than the rights of an unsecured general creditor of the Company. 

	 	9.3	 	Rights Not Transferable or Subject to Alienation. No rights granted to an Eligible Director under this DCM Plan may be sold, assigned or otherwise transferred by the Eligible
Director other than by will or the laws of descent or distribution; all rights granted to an Eligible Director under this DCM Plan may be exercised during the Eligible Director’s lifetime only by such Eligible Director. An Eligible
Director’s rights to payments under the DCM Plan are not subject in any manner to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment or garnishment by his creditors or his beneficiaries.

  

	10.	 	DCM Plan Amendments and Termination. The Board may suspend or terminate the DCM Plan at any time and may amend it at any time, in whole or in part, provided that no
amendment or termination may adversely affect any rights of any Eligible Director that have accrued prior to the date of such amendment or termination, and provided, further, that any amendment for which shareholder approval is required by law,
shall not be effective until such approval has been obtained. 

  

	11.	 	Right of Discharge Reserved. Nothing in the DCM Plan shall confer upon any Eligible Director the right to continue in the service of the Company or affect any right
that the Company may have to terminate the service of such Eligible Director. 

  

	12.	 	Other Payments or Awards. Nothing contained in the DCM Plan shall be deemed in any way to limit or restrict the Company, any affiliate, or the Board from making any
award or payment to any person under any other plan, arrangement or understanding, whether now existing or hereafter in effect, other than by use of the shares authorized under the Company’s 2001 Non-Employee Director Stock Plan, including any
successor plan. 

  

	13.	 	Severability. If any portion of the DCM Plan is declared by any court or governmental authority to be invalid, such invalidity shall not affect any portion not
declared to be invalid. Any portion so declared to be invalid shall, if possible, be construed in a manner which will give effect to the terms of such portion to the fullest extent possible while remaining valid. 

  

	14.	 	Notices. All notices and other communications hereunder shall be given in writing and shall be personally delivered or sent by registered or certified mail, return
receipt requested, or by reputable overnight delivery service. Any notice shall be deemed given on the date of delivery or mailing, and if mailed, shall be addressed (a) to the Company, at 85 Swanson Road, Boxborough, MA 01719, Attention: DCM
Committee (c/o Secretary), and (b) to an Eligible Director, at the Eligible Director’s principal residential address last furnished to the Company. Either party may, by notice, change the address to which notice to such party is to be given.

  

	15.	 	Section Headings. The Section headings contained herein are for convenience only and are not intended to define or limit the contents of said Sections.

	

  

	16.	 	Effective Date. This DCM Plan shall become effective immediately upon the approval of the DCM Plan by the Board, as reflected in a Board Resolution (the “DCM Plan
Effective Date”). 

  

	17.	 	Exculpation. It is understood that the obligations incurred by the Company with respect to this DCM Plan do not constitute personal obligations of the Directors,
officers, employees or shareholders and shall not create or involve any claim against, or personal liability on the part of, them or any of them. The Eligible Directors agree not to seek recourse against any such Directors, officers, employees or
shareholders, or any of them or any of their personal assets for satisfaction of any liability under or with respect to the DCM Plan.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}]]